GlassScriptPhysician profile
Bridget V Rund
NPI 1528376779
$6,098.43
in general payments reported to CMS, 2019-2025
35 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $695 · 2022: $729 · 2023: $986 · 2024: $1,443 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $863.99 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $784.09 | 2021-2025 | |
| Alkermes, INC. | $684.30 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $579.82 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $496.96 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $390.35 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $371.08 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $293.85 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.49 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $200.10 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $170.96 | 2023-2025 | Auvelity |
| Gilead Sciences, INC. | $128.13 | 2023-2025 | |
| Noven Therapeutics, LLC | $110.95 | 2024-2025 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $85.09 | 2023-2024 | Quviviq |
| Indivior INC. | $70.86 | 2022-2024 | Perseris |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.71 | 2021-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $66.84 | 2022-2025 | Qelbree, Qelbree |
| Exact Sciences Corporation | $53.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $53.23 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $47.49 | 2021-2022 | |
| Verona Pharma, INC. | $36.17 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $33.31 | 2021-2023 | Veozah |
| Viiv Healthcare Company | $33.10 | 2025 | Apretude |
| Ironshore Pharmaceuticals INC. | $28.62 | 2022-2023 | Jornay Pm |
| Glaxosmithkline, LLC. | $24.40 | 2021 | |
| Abbott Laboratories | $22.81 | 2023 | Freestyle Libre 3 |
| Tris Pharma INC | $20.86 | 2024 | Dyanavel Xr |
| Corium, LLC | $16.17 | 2022 | |
| Novo Nordisk INC | $15.92 | 2023 | |
| Amarin Pharma, INC. | $15.26 | 2021 | |
| Ucb, INC. | $15.06 | 2023 | Briviact |
| Dexcom, INC. | $15.02 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $13.52 | 2024 | Voquezna |
| Ardelyx, INC. | $13.44 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Rund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.